Description: Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. The company has collaboration agreements with Johnson & Johnson to jointly develop and commercialize aprocitentan and its derivative compounds or products; Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy; and collaboration agreement with ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Home Page: www.idorsia.com
Hegenheimermattweg 91
Allschwil,
4123
Switzerland
Phone:
41 58 844 10 10
Officers
| Name | Title |
|---|---|
| Mr. Andre C. Muller | Executive VP & CFO |
| Dr. Martine Clozel | Executive VP & Chief Scientific Officer |
| Dr. Guy Braunstein M.D. | Executive VP & Chief Medical Officer |
| Mr. Alberto Gimona M.D. | Executive VP & Head of Global Clinical Development |
| Mr. Andrew C. Weiss C.F.A. | Senior VP and Head of Investor Relations & Corporate Communications |
| Mr. Julien Gander L.L.M. | Senior VP, Group General Counsel & Company Secretary |
| Mr. Alexander Khatuntsev | Senior VP & Head of Global Human Resources |
| Mr. Olivier Lambert | Senior VP & Head of Technical Operations |
| Mr. Markus A. Riederer | Senior VP & Head of Drug Discovery Biology |
| Mr. Christoph Boss | Senior VP & Head of Drug Discovery Chemistry |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 28.0845 |
| Price-to-Sales TTM: | 4.3347 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |